J&J-TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma

TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma

强生(US:JNJ) Prnewswire·2025-09-19 20:30

临床研究结果 - 一项研究性免疫诱导治疗方案在2期MajesTEC-5研究中显示出有意义的临床疗效 [1] - 该方案结合了TECVAYLI和DARZALEX FASPRO两种药物 [1] - 治疗对象为新诊断多发性骨髓瘤且适合移植的患者 [1] 治疗效果数据 - 100%的可评估患者在诱导治疗后达到了微小残留病灶阴性 [1]

J&J-TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma - Reportify